| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1040719603 |
| P356 | DOI | 10.2165/00003495-200565170-00006 |
| P698 | PubMed publication ID | 16296874 |
| P50 | author | Matthew E. Falagas | Q87082633 |
| P2093 | author name string | Sofia K Kasiakou | |
| Kenneth R Lawrence | |||
| Nicolaos Choulis | |||
| P2860 | cites work | Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy | Q24519008 |
| Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients | Q28323566 | ||
| Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial | Q28359772 | ||
| Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa | Q30775587 | ||
| Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance | Q33543130 | ||
| Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients | Q33694347 | ||
| Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery | Q33695230 | ||
| Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit | Q33979524 | ||
| Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study | Q33982863 | ||
| Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections | Q33983119 | ||
| Does the dose matter? | Q34347926 | ||
| Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. | Q34824085 | ||
| Feasibility of Administering Aminoglycoside Antibiotics by Continuous Intravenous Infusion | Q34942199 | ||
| Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion | Q35013772 | ||
| Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion | Q35013838 | ||
| Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. | Q35121441 | ||
| Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections | Q35123123 | ||
| Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections | Q35123139 | ||
| Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers | Q35284383 | ||
| Continuous infusion of beta-lactam antibiotics | Q35656806 | ||
| Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis | Q35810298 | ||
| Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients | Q35814807 | ||
| Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials | Q36240858 | ||
| Assessment of cefazolin and cefuroxime tissue penetration by using a continuous intravenous infusion | Q39816206 | ||
| Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion | Q40518317 | ||
| Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer. | Q40569623 | ||
| Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation | Q40573363 | ||
| Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital | Q40585005 | ||
| Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation | Q40620124 | ||
| Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients | Q40622240 | ||
| Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia | Q40688395 | ||
| Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients | Q40776303 | ||
| A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients | Q40866399 | ||
| Pharmacological study of cefazolin during intermittent and continuous infusion: a crossover investigation in humans | Q40947232 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Constant rate infusion of vancomycin in premature neonates: a new dosage schedule | Q41883396 | ||
| Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole | Q42255800 | ||
| Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients | Q42689134 | ||
| Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia | Q43410703 | ||
| Serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients | Q43575062 | ||
| Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia | Q43633624 | ||
| The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis | Q43693149 | ||
| Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients | Q43693161 | ||
| A comparative trial of sisomicin therapy by intermittent versus continuous infusion | Q43703442 | ||
| Population pharmacokinetics of continuous infusion ceftazidime | Q43708599 | ||
| Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections | Q43823469 | ||
| Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections | Q43829748 | ||
| Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing | Q44104691 | ||
| "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy | Q44157139 | ||
| Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia | Q44287991 | ||
| A pilot study to determine the feasibility of continuous cefazolin infusion | Q44320354 | ||
| Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care u | Q44342577 | ||
| Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study | Q44396642 | ||
| Continuous infusion versus intermittent administration of meropenem in critically ill patients | Q44483233 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia | Q44584395 | ||
| Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study | Q44678115 | ||
| Continuous versus intermittent cefepime infusion in critical care. Preliminary results | Q44775184 | ||
| Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis | Q44930989 | ||
| High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion | Q44991015 | ||
| Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin | Q46984010 | ||
| Pharmacokinetics and nephrotoxicity of continuous intravenous infusion of gentamicin in low birth weight infants | Q47204812 | ||
| Intermittent bolus dosing of ceftazidime in critically ill patients. | Q51537569 | ||
| Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. | Q52076636 | ||
| Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. | Q52081789 | ||
| Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. | Q53945242 | ||
| Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. | Q54149026 | ||
| Treatment of gram-negative bacillary septicemia with cefoperazone. | Q54486351 | ||
| The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis | Q56745973 | ||
| Continuous infusion ceftazidime in intensive care: a randomized controlled trial | Q57955147 | ||
| Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers | Q59417424 | ||
| Concentrations of Netilmicin in Bronchial Secretions and Serum during Intermittent vs. Continuous Infusion: A Crossover Study in Humans | Q66973625 | ||
| Kinetics and dose calculations of ampicillin and gentamicin given as continuous intravenous infusion during parenteral nutrition in 88 newborn infants | Q70455177 | ||
| Administration of gentamicin and ampicillin by continuous intravenous infusion to newborn infants during parenteral nutrition | Q71598261 | ||
| Tissue concentrations of mezlocillin in benign hypertrophy of the prostate following intravenous bolus injection versus infusion | Q72712296 | ||
| Intermittent and continuous ceftazidime infusion for critically ill trauma patients | Q72998867 | ||
| Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children | Q73330360 | ||
| Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h versus intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers | Q73508331 | ||
| Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime | Q73567522 | ||
| Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics | Q73568583 | ||
| Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis | Q73738224 | ||
| Continuous infusion of ceftazidime with an elastomeric infusion device | Q74183063 | ||
| A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis | Q77759877 | ||
| P433 | issue | 17 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 2499-2511 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters | |
| P478 | volume | 65 |
| Q38862567 | Antibiothérapie du sujet âgé : On peut toujours mieux faire. |
| Q37867266 | Antimicrobial stewardship in the intensive care unit: a focus on potential pitfalls |
| Q36523688 | Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens |
| Q34892334 | Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis |
| Q36329228 | Continuous beta-lactam infusion in critically ill patients: the clinical evidence |
| Q48274760 | Continuous or Extended Intravenous Administration of β-Lactam Antibiotics |
| Q24199096 | Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections |
| Q26853629 | Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics |
| Q37139730 | Meropenem: a review of its use in the treatment of serious bacterial infections. |
| Q42288294 | National survey on continuous and extended infusions of antibiotics |
| Q36911111 | Pharmacokinetics and pharmacodynamics of antibacterial agents |
| Q64131294 | Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico |
| Q64131298 | Resumen de las recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos gram positivos en el paciente crítico |
| Q38079526 | Review of continuous-infusion vancomycin |
| Q49056677 | Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients |
| Q35986250 | Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases |
| Q47939381 | The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role? |
| Q36607415 | Treatment of Pseudomonas aeruginosa infection in critically ill patients |
| Q36791058 | Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly |
| Q38004063 | β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review |
Search more.